Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMAT: Metastasectomy of lung metastases in poor-prognosis clear cell renal cell carcinoma with or without adjuvant sunitinib
2008-007609-36Phase 2Terminated
- Sponsor
- University of Duisburg-Essen
- Start
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of sunitinib in clear cell renal cell carcinoma (ccRCC) and renal cell carcinoma (RCC) (2 arms), sponsored by University of Duisburg-Essen. Primary endpoint: Recurrence-free survival at 2 years. Started May 2010; status: terminated.
02
Drugs
sunitinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2008-007609-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007609-36.